Free tool
FAERS Monitor: Zyrtec Hives
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019835 or its brand name (Zyrtec Hives, Cetirizine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
31,596
Serious
24,286
77% of reports
Hospitalization
9,676
Death reported
5,136
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9,579
- pain8,991
- fatigue8,958
- alopecia7,543
- rheumatoid arthritis7,476
- abdominal discomfort7,454
- systemic lupus erythematosus7,162
- pemphigus7,032
- off label use6,788
- rash6,699
- glossodynia6,534
- swelling6,095
- hypersensitivity5,816
- hand deformity5,688
- infusion related reaction5,618
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 60 |
| 2006 | 20 |
| 2007 | 66 |
| 2008 | 176 |
| 2009 | 162 |
| 2010 | 138 |
| 2011 | 138 |
| 2012 | 169 |
| 2013 | 243 |
| 2014 | 263 |
| 2015 | 381 |
| 2016 | 833 |
| 2017 | 894 |
| 2018 | 1,027 |
| 2019 | 1,560 |
| 2020 | 2,161 |
| 2021 | 4,406 |
| 2022 | 4,409 |
| 2023 | 3,424 |
| 2024 | 4,292 |
| 2025 | 4,069 |
| 2026 | 2,686 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,563 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 7,032 | 853.5 | 825.3 | 2,624,177 |
| hand deformitySignal | 5,688 | 508.5 | 492.2 | 1,633,776 |
| glossodyniaSignal | 6,534 | 273.9 | 266.7 | 1,259,584 |
| systemic lupus erythematosusSignal | 7,162 | 168.0 | 164.1 | 950,661 |
| infusion related reactionSignal | 5,618 | 61.5 | 60.0 | 307,199 |
| rheumatoid arthritisSignal | 7,476 | 46.9 | 45.9 | 315,060 |
| swellingSignal | 6,095 | 46.3 | 45.2 | 253,652 |
| abdominal discomfortSignal | 7,454 | 30.9 | 30.3 | 207,770 |
| alopeciaSignal | 7,543 | 26.5 | 26.0 | 179,996 |
| hypersensitivitySignal | 5,816 | 21.5 | 21.0 | 111,077 |
| rashSignal | 6,699 | 10.4 | 10.2 | 57,047 |
| painSignal | 8,991 | 9.9 | 9.7 | 72,767 |
| fatigueSignal | 8,958 | 7.7 | 7.6 | 53,933 |
| off label useSignal | 6,788 | 5.2 | 5.1 | 23,789 |
| drug ineffectiveSignal | 9,579 | 4.9 | 4.8 | 31,161 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.